Is KALV undervalued or overvalued?
As of 2025-03-25, the Intrinsic Value of Kalvista Pharmaceuticals Inc (KALV) is -15.82 USD. This KALV valuation is based on the model Peter Lynch Fair Value. With the current market price of 11.89 USD, the upside of Kalvista Pharmaceuticals Inc is -233.07%. This means that KALV is overvalued by 233.07%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -15.82 - -15.82 | -15.82 | -233.07% |
| P/E | (15.82) - (48.10) | (32.83) | -376.1% |
| DDM - Stable | (22.55) - (71.77) | (47.16) | -496.6% |
| DDM - Multi | (8.30) - (21.09) | (11.97) | -200.7% |
| Market Cap (mil) | 591.17 |
| Beta | 0.55 |
| Outstanding shares (mil) | 49.72 |
| Enterprise Value (mil) | 334.40 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.90% |
| Cost of Debt | 5.00% |
| WACC | 7.28% |